Shalom Guy, Zisman Devy, Harman-Boehm Ilana, Biterman Haim, Greenberg-Dotan Sari, Polishchuk Ilya, Moser Hadas, Freud Tamar, Feldhamer Ilan, Cohen Arnon D
Department of Dermatology and Venereology, Soroka Medical Center, P.O.B. 151, 84101 Beer-Sheva, Israel.
Acta Derm Venereol. 2015 Nov;95(8):973-7. doi: 10.2340/00015555-2130.
Drug survival has recently become an important clinical issue in psoriasis. However, there has been little research into factors associated with drug survival of methotrexate and acitretin. The aim of this study was to investigate factors associated with drug survival of methotrexate and acitretin treatment for psoriasis. Survival analysis was performed in patients who received methotrexate or acitretin for the treatment of psoriasis, drawn from the Clalit Health Services database. Investigated factors included demographic variables, obesity, metabolic syndrome, psoriatic arthritis, administration route and folic acid supplementation. Among 6,256 patients, factors associated with treatment drop-out were: younger age (p <0.001) and psoriatic arthritis (acitretin p < 0.001). For methotrexate, metabolic syndrome (p = 0.033), intramuscular administration route of injection (p <0.001) and lack of folic acid supplementation (p <0.001) were associated with treatment drop-out. In patients with psoriasis, some ancillary factors may modify the drug survival of acitretin and methotrexate.
药物留存率最近已成为银屑病领域一个重要的临床问题。然而,关于与甲氨蝶呤和阿维A药物留存率相关因素的研究却很少。本研究的目的是调查与甲氨蝶呤和阿维A治疗银屑病的药物留存率相关的因素。对从克拉利特医疗服务数据库中选取的接受甲氨蝶呤或阿维A治疗银屑病的患者进行了生存分析。调查的因素包括人口统计学变量、肥胖、代谢综合征、银屑病关节炎、给药途径和叶酸补充情况。在6256名患者中,与治疗中断相关的因素有:年龄较小(p <0.001)和银屑病关节炎(阿维A,p < 0.001)。对于甲氨蝶呤,代谢综合征(p = 0.033)、肌肉注射给药途径(p <0.001)和未补充叶酸(p <0.001)与治疗中断相关。在银屑病患者中,一些辅助因素可能会改变阿维A和甲氨蝶呤的药物留存率。